Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Timing of Initiation of Sulphonylurea Therapy on Neurodevelopmental Outcomes in Individuals With Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome Due to the V59M Mutation in the KCNJ11 Gene

NCT05751525 is registered in ClinicalTrials.gov with Royal Devon and Exeter NHS Foundation Trust as lead sponsor.

NCT NCT05751525
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05751525 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Timing of Initiation of Sulphonylurea Therapy on Neurodevelopmental Outcomes in Individuals With Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome Due to the V59M Mutation in the KCNJ11 Gene
Lead sponsor
Royal Devon and Exeter NHS Foundation Trust
Phase
Observational
Overall status
Unknown status
Start date
July 1, 2016
Completion date
December 31, 2025
Enrollment
21 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

adhd, autism spectrum disorder, development delay, epilepsy, intellectual disability, neurodevelopmental disorders